TPOXX® Antiviral Treatment (Tecovirimat)

Department of Health and Social Care (DHSC)contractContracts FinderRef CF-1166800D0O000000rwimUAAcomplete
View buyer

Estimated value

£1

Awarded value

£1

Awarded 27 Jul 2022

Suppliers

1

Lots

1

1 awarded

Published

04 Nov 2022

Deadline 27 Jul 2022

Description

The monkeypox virus belongs to a family of viruses called orthopox viruses and the drug Tecovirimat is an antiviral designed specifically to treat viral infections of this kind. In the current outbreak, Tecovirimat has been successfully used to treat patients with the most severe presentations of monkeypox virus infection. This contract is for a small supply of TPOXX® Antiviral Treatment (Tecovirimat) for the treatment of severe cases of Monkeypox in the UK. Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate the price per dose. Publication of this information would therefore: (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors; and (iii) impact fair competition between vendors.

Scope

Reference
CF-1166800D0O000000rwimUAA
Total value
£1 excluding VAT
Commercial tool
Standalone contract
Contract dates
27 Jul 2022 to 26 Jul 2023
CPV classifications
33651400

Submission & procedure

Submission deadline
27 Jul 2022, 11:00 am

Award details

Awarded supplier(s), contract period and value as published in the award notice.

Awarded value

£1

Award date

27 Jul 2022

Contract start

27 Jul 2022

Contract end

26 Jul 2023